Jardiance ® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
Jardiance ® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance | Research